摘要
目的研究人脑胶质瘤的microRNA-128(miR-128)表达水平及IDH1突变型、MGMT、Ki-67蛋白表达与胶质瘤病理分级、预后的关系。方法收集脑胶质瘤手术标本21例,其中病理分级低级别者13例、高级别者8例;脑外伤清除组织6例。采用实时定量PCR法检测胶质瘤标本及胶质瘤细胞株U87、人小胶质细胞株HMC3的miR-128表达水平;用免疫组织化学法检测胶质瘤标本IDH1突变型及MGMT、Ki-67蛋白表达水平。结果miR-128在低级别胶质瘤的表达水平明显高于高级别胶质瘤,在胶质瘤细胞株U87的表达水平明显低于人小胶质细胞株HMC3(P<0.01,P<0.05)。生存曲线分析显示,IDH1突变型、MGMT阴性表达及Ki-67≤10%患者的生存期分别比IDH1野生型、MGMT阳性表达及Ki-67>10%患者明显延长(P<0.05~0.001)。IDH1突变型、MGMT阴性表达及Ki-67≤10%患者的miR-128表达水平分别比野生型、MGMT阴性表达及Ki-67>10%患者明显增高(P<0.05~0.001)。结论miR-128在低级别胶质瘤的表达水平明显高于高级别胶质瘤。IDH1突变型、MGMT阴性表达、Ki-67≤10%胶质瘤的miR-128表达水平更高,也预示患者的预后更好。miR-128可以作为脑胶质瘤诊断和治疗效果及预后预测的生物标志物。
Objective To study the expression of microRNA-128(miR-128),IDH1 mutation,MGMT and Ki-67 in human glioma and their relationship with pathological grade and prognosis.Methods 21 surgical specimens of glioma were collected,including 13 cases of low grade and 8 cases of high grade,and 6 cases of brain trauma.Real time quantitative PCR was used to detect the expression of miR-128 in glioma samples,glioma cell line U87 and human microglia cell line HMC3.Immunohistochemistry was used to detect the expression of IDH1 mutation,MGMT and Ki-67 in glioma samples.Results The expression level of miR-128 in low-grade gliomas was significantly higher than that in high-grade gliomas,and the expression level in glioma cell line U87 was significantly lower than that in human microglia cell line hmc3(P<0.01,P<0.05).Survival curve analysis showed that the survival time of IDH1 mutant,Mgmt negative expression and Ki-67≤10%patients was significantly longer than that of IDH1 wild type,Mgmt positive expression and Ki-67>10%patients(P<0.05~0.001).The expression levels of miR-128 in IDH1 mutant,Mgmt negative expression and Ki-67≤10%patients were significantly higher than those in wild type,Mgmt negative expression and Ki-67>10%patients(P<0.05~0.001).Conclusions The expression level of miR-128 in low-grade gliomas was significantly higher than that in high-grade gliomas.The higher expression of miR-128 in IDH1 mutant,Mgmt negative expression and Ki-67≤10%glioma also indicates better prognosis.MiR-128 can be used as a biomarker for the diagnosis,treatment and prognosis of glioma.
作者
赵伟
张旭
岳芳倩
沈承恩
柳神海
王峰
ZHAO Wei;ZHANG Xu;YUE Fang-qian(Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan 750004, China)
出处
《临床神经外科杂志》
CAS
2021年第1期53-57,共5页
Journal of Clinical Neurosurgery
基金
宁夏回族自治区“十三五”重大科技专项(2018BFG02007)。
